CARMAT overview

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, informs its shareholders that the Combined General Meeting (AGM) held on May 11, 2023 was able to validly deliberate, the required quorum having been reached. The AGM adopted all proposed resolutions, with the exception of the 28 th resolution which was...

Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from advanced biventricular heart failure, today announced the publication of the Company’s Universal registration document for the year ended December 31, 2022. The document, filed with the French stock-market authority ( Autorité des Marchés Financiers...

Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, today announces that it has obtained non-dilutive financing of €13.2 million as part of the “France 2030” plan, and the extension of its cash runway through to mid-October 2023. Non-dilutive financing of €13.2 million to increase and...

Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, today announced that the first U.S. clinical experience with Aeson® has been published in the Annals of Thoracic Surgery Short Reports, the journal of the U.S. Society of Thoracic Surgeons. The article, entitled The First Autoregulated...

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, today announces its annual results for the year ending December 31, 2022 1 and confirms its 2023 objectives. Stéphane Piat, Chief Executive Officer of CARMAT, said: “ Thanks to the efforts of the whole CARMAT team, we have achieved our main objective for...

Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), designer and developer of Aeson ® , the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, provides a business update, and communicates its financial targets for the first time. Sales forecast of €10 to €13 million in 2023 CARMAT resumed commercial implants of its Aeson ® artificial heart in November 2022. The Company...

Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces today that it will hold a video conference in English to provide an update on its developments. Date/time: Monday, January 23, 2023 at 8 pm (CET) The conference will be hosted by: Stéphane Piat, Chief Executive...